Given the high prevalence of EBV and its ability to establish lifelong persistent infections with the potential for reactivation, TLR9 inhibitors may serve as a potential therapeutic tool to be considered for RA management in EBV-infected individuals. The gene discussed is TLR9; the disease is rheumatoid arthritis.